Cargando…

A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab

OBJECTIVE: Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, is effective for treating eosinophilic severe asthma. However, there is a need for more biomarkers that can predict the patient response to mepolizumab before starting therapy. This study aimed to identify a new biomarker in...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzukawa, Maho, Ohshima, Nobuharu, Tashimo, Hiroyuki, Asari, Isao, Kobayashi, Nobuyuki, Shoji, Shunsuke, Tohma, Shigeto, Ohta, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725639/
https://www.ncbi.nlm.nih.gov/pubmed/32713920
http://dx.doi.org/10.2169/internalmedicine.5159-20
_version_ 1783620741031264256
author Suzukawa, Maho
Ohshima, Nobuharu
Tashimo, Hiroyuki
Asari, Isao
Kobayashi, Nobuyuki
Shoji, Shunsuke
Tohma, Shigeto
Ohta, Ken
author_facet Suzukawa, Maho
Ohshima, Nobuharu
Tashimo, Hiroyuki
Asari, Isao
Kobayashi, Nobuyuki
Shoji, Shunsuke
Tohma, Shigeto
Ohta, Ken
author_sort Suzukawa, Maho
collection PubMed
description OBJECTIVE: Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, is effective for treating eosinophilic severe asthma. However, there is a need for more biomarkers that can predict the patient response to mepolizumab before starting therapy. This study aimed to identify a new biomarker in the serum that is able to accurately predict the responsiveness to mepolizumab. METHODS: This study enrolled 11 patients who had all been diagnosed with severe eosinophilic asthma and were then administered mepolizumab every 4 weeks for at least 4 months. Blood samples were collected, and pulmonary function tests and questionnaires were administered at baseline and after 4, 8 and 16 weeks of treatment. The response to mepolizumab was then assessed based on the difference in the Asthma Quality of Life Questionnaire (AQLQ) score after 16 weeks of mepolizumab therapy compared with that at baseline. Patients with an increase in the AQLQ score of more than 0.5 were defined as responders. The cytokine levels in the blood were measured by LUMINEX 200 and ELISA. RESULTS: There were 6 responders and 5 non-responders. The responders showed a significantly lower serum level of chemokine (C-C motif) ligand 4/macrophage inflammatory protein-1β (CCL4/MIP-1β) at baseline compared to the non-responders. Receiver operating characteristic curves to distinguish responders from non-responders using the baseline serum CCL4/MIP-1β level showed a good area under the curve of 0.9. The non-responders showed a significant increase in the level of CCL4/MIP-1β after 4 weeks compared to the baseline. CONCLUSION: A low baseline serum CCL4/MIP-1β level may be useful for predicting a good mepolizumab response in severe eosinophilic asthma.
format Online
Article
Text
id pubmed-7725639
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-77256392020-12-21 A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab Suzukawa, Maho Ohshima, Nobuharu Tashimo, Hiroyuki Asari, Isao Kobayashi, Nobuyuki Shoji, Shunsuke Tohma, Shigeto Ohta, Ken Intern Med Original Article OBJECTIVE: Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, is effective for treating eosinophilic severe asthma. However, there is a need for more biomarkers that can predict the patient response to mepolizumab before starting therapy. This study aimed to identify a new biomarker in the serum that is able to accurately predict the responsiveness to mepolizumab. METHODS: This study enrolled 11 patients who had all been diagnosed with severe eosinophilic asthma and were then administered mepolizumab every 4 weeks for at least 4 months. Blood samples were collected, and pulmonary function tests and questionnaires were administered at baseline and after 4, 8 and 16 weeks of treatment. The response to mepolizumab was then assessed based on the difference in the Asthma Quality of Life Questionnaire (AQLQ) score after 16 weeks of mepolizumab therapy compared with that at baseline. Patients with an increase in the AQLQ score of more than 0.5 were defined as responders. The cytokine levels in the blood were measured by LUMINEX 200 and ELISA. RESULTS: There were 6 responders and 5 non-responders. The responders showed a significantly lower serum level of chemokine (C-C motif) ligand 4/macrophage inflammatory protein-1β (CCL4/MIP-1β) at baseline compared to the non-responders. Receiver operating characteristic curves to distinguish responders from non-responders using the baseline serum CCL4/MIP-1β level showed a good area under the curve of 0.9. The non-responders showed a significant increase in the level of CCL4/MIP-1β after 4 weeks compared to the baseline. CONCLUSION: A low baseline serum CCL4/MIP-1β level may be useful for predicting a good mepolizumab response in severe eosinophilic asthma. The Japanese Society of Internal Medicine 2020-07-21 2020-11-15 /pmc/articles/PMC7725639/ /pubmed/32713920 http://dx.doi.org/10.2169/internalmedicine.5159-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Suzukawa, Maho
Ohshima, Nobuharu
Tashimo, Hiroyuki
Asari, Isao
Kobayashi, Nobuyuki
Shoji, Shunsuke
Tohma, Shigeto
Ohta, Ken
A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab
title A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab
title_full A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab
title_fullStr A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab
title_full_unstemmed A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab
title_short A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab
title_sort low serum ccl4/mip-1β level may predict a severe asthmatic responsiveness to mepolizumab
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725639/
https://www.ncbi.nlm.nih.gov/pubmed/32713920
http://dx.doi.org/10.2169/internalmedicine.5159-20
work_keys_str_mv AT suzukawamaho alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT ohshimanobuharu alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT tashimohiroyuki alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT asariisao alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT kobayashinobuyuki alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT shojishunsuke alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT tohmashigeto alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT ohtaken alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT suzukawamaho lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT ohshimanobuharu lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT tashimohiroyuki lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT asariisao lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT kobayashinobuyuki lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT shojishunsuke lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT tohmashigeto lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab
AT ohtaken lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab